The Medicinal Chemistry Department has a strong record of achievement, including the synthesis and discovery of more than 20 compounds that entered clinical trials and seven drugs with FDA approval. Our staff currently focuses on three primary therapeutic areas: cancer, infectious diseases, and CNS/neurological diseases. We utilize modern discovery techniques including structural biology and X-ray crystallography, molecular modeling & computer-assisted drug design (CADD), parallel synthesis, and high-throughput screening to generate novel therapeutics. Our discovery initiatives result from collaborations with pharmaceutical companies, NIH-funded basic research grants, and internal research projects. Among grant-funded programs, the Medicinal Chemistry Department has major ongoing projects in the Southeast Regional Center of Excellence for Biodefense (SERCEB), the NINDS Drug Screening Facility for Neurodegenerative Disease, and the NIH Roadmap Molecular Libraries Probe Production Centers Network (MLPCN). In addition to these efforts, the Department occasionally undertakes custom synthesis projects, and actively seeks collaborative licensing opportunities for our unique in-house chemical repository.
Learn more about our senior staff.